ARIAD Announces Presentations of Preclinical Data at American Association for Cancer Research Annual Meeting

Article

ARIAD Pharmaceuticals, Inc today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2012, taking place Saturday, March 31 through Wednesday, April 4, 2012, in Chicago.

PRESS RELEASE

ARIAD Pharmaceuticals, Inc today announced its schedule of preclinical data presentations to be made at the American Association for Cancer Research (AACR) Annual Meeting 2012, taking place Saturday, March 31 through Wednesday, April 4, 2012, in Chicago.

Listed below are the details of presentations at AACR that describe ARIAD’s product candidates or research programs. There will be three presentations of data on ARIAD’s investigational targeted therapies, ponatinib and AP26113; and one presentation of work on choline kinase, a discovery program which is not being pursued further at this time. Each presentation is currently available in abstract form:

Title: Ponatinib, a potent pan-BCR-ABL inhibitor, retains activity against gatekeeper mutants of FLT3, RET, KIT, PDGFRα/β and FGFR1

Date & Time: Sunday, April 1, 1:00—5:00 p.m. (Poster)

Abstract: #853

Location: Hall F, Poster Section 32

Title: AP26113 is a dual ALK/EGFR inhibitor: Characterization against EGFR T790M in cell and mouse models of NSCLC

Date & Time: Monday, April 2, 8:00 a.m.—12:00 p.m. (Poster)

Abstract: #1794

Location: Hall F, Poster Section 29

Title: Fibroblast growth factors in head and neck cancer: Genetic alterations and therapeutic targeting with ponatinib

Date & Time: Monday, April 2, 1:00—5:00 p.m. (Poster)

Abstract: #2832

Location: Hall F, Poster Section 32

Title: Small molecule inhibitors of choline kinase lead to reduced phosphocholine levels and induction of apoptosis in cancer cells

Date & Time: Tuesday, April 3, 8:00 a.m.—12:00 p.m. (Poster)

Abstract: #3236

Location: Hall F, Poster Section 9

About ARIAD

ARIAD Pharmaceuticals, Inc. is an emerging global oncology company focused on the discovery, development and commercialization of medicines to transform the lives of cancer patients. ARIAD’s approach to structure-based drug design has led to three internally discovered, molecularly targeted product candidates for drug-resistant or difficult-to-treat cancers, including certain forms of chronic myeloid leukemia, soft tissue and bone sarcomas and non-small cell lung cancer. For additional information, visit http://www.ariad.com or follow us on Twitter.

Source: ARIAD Pharmaceuticals, Inc.

Related Videos
Image Credit: SciePro - stock.adobe.com
Pharmacist selling medications in the pharmacy | Image Credit: rh2010 - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.